The mechanism of granulocytopenia is unknown, but inhibition of cell release from the bone marrow has been suggested. A sustained increase in serum triglyceride levels has been reported. Diabetes mellitus may worsen or develop. The cases of pneumonitis may also be due to the use of Sho-Saiko and interferon. This array of side effects indicates the importance of selecting patients for therapy and optimizing response.
Careful assessment is required before treatment, and monitoring is required during treatment.
Relatively little is known about the mechanisms of many of the side effects of interferon alpha. References Fattovich G, Giustina G, Favarato S, Ruol A, Macarri G, Orlandi F, Iaquinto G, Ambrosone L, Francavilla A, Pastore G, Santantonio MT, Romagno D, Bolondi L, Sofia S, Marchesini A, Pisi E, Mazzella G, Roda E, Attaro L, Chiodo F, Mori F, Verucchi G, Lanzini A, Salmi A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. Russello M, Vasquez E, Fraggetta F, Zammataro M. Recombinant interferon alpha therapy in elderly patients with chronic hepatitis C without cirrhosis. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. Seizures during alpha interferon therapy.